Endocannabinoid signal in the gut controls dietary fat intake

Nicholas V. DiPatrizio*, Giuseppe Astaritaab, Gary Schwartz, Xiaosong Li, and Daniele Piomelliab,d

*Departments of Pharmacology and bBiological Chemistry, University of California, Irvine, School of Medicine, Irvine, CA 92693; dUnit of Drug Discovery and Development, Italian Institute of Technology, 16163 Genoa, Italy; and dDiabetes Research Center, Departments of Medicine and Neuroscience, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY 10461

Edited by Leslie Lars Iversen, University of Oxford, Oxford, United Kingdom, and approved June 6, 2011 (received for review March 23, 2011)

Oral sensory signals drive dietary fat intake, but the neural mechanisms underlying this process are largely unknown. The endocannabinoid system has gained recent attention for its central and peripheral roles in regulating food intake, energy balance, and reward. Here, we used a sham-feeding paradigm, which isolates orosensory from postigestive influences of foods, to examine whether endocannabinoid signaling participates in the positive feedback control of fat intake. Sham feeding a lipid-based meal stimulated endocannabinoid mobilization in the rat proximal small intestine by altering enzymatic activities that control endocannabinoid metabolism. This effect was abolished by surgical transection of the vagus nerve and was not observed in other peripheral organs or in brain regions that control feeding. Sham feeding of a nutritionally complete liquid meal produced a similar response to that of fat, whereas protein or carbohydrate alone had no such effect. Local infusion of the CB1-cannabinoid receptor antagonist, rimonabant, into the duodenum markedly reduced fat sham feeding. Similarly to rimonabant, systemic administration of the peripherally restricted CB2-receptor antagonist, URB 447, attenuated sham feeding of lipid. Collectively, the results suggest that the endocannabinoid system in the gut exerts a powerful regulatory control over fat intake and might be a target for antiobesity drugs.

Mammals have an adaptive advantage in seeking fat-rich foods, which are nutritionally essential but scarce in most natural habitats. This innate preference can become maladaptive, however, when it is not limited by environmental constraints. Indeed, the unrestricted availability of fatty foods, which characterizes diets of industrialized societies, is considered to be a key contributing factor for obesity, diabetes, and cardiovascular disease (1). Despite its theoretical and practical significance, fat preference is still incompletely understood.

In the present study, we examined whether endogenous cannabinoid substances participate in the control of dietary fat intake. The endocannabinoids are a family of biologically active lipids that bind to and activate CB1- and CB2-cannabinoid receptors, the G protein-coupled receptors targeted by Δ9-tetrahydrocannabinol in Cannabis. They include several derivatives of arachidonic acid, which are generated on demand by neurons and other cells in response to physiological or pathological stimuli. The two best-characterized endocannabinoids are 2-arachidonoyl-sn-glycerol (2-AG) and anandamide (2). 2-AG is produced through a two-step mechanism in which phospholipase C-δ activation causes the generation of 1,2-diacylglycerol, which is subsequently cleaved by diacylglycerol lipase-α to yield 2-AG (3). Anandamide production, however, is thought to occur via phospholipase C-mediated hydrolysis of N-arachidonoyl phosphatidylethanolamine (4, 5), although alternative pathways have been proposed (6). The biological actions of 2-AG and anandamide are terminated by a combination of facilitated diffusion into cells followed by intracellular enzyme-mediated hydrolysis (2).

The proposed role of endocannabinoids in the hedonic evaluation (‘liking’) of palatable foods (7, 8) prompted us to ask whether these lipid mediators might be involved in the positive feedback mechanism originating in the mouth, which maintains fat intake once it has begun (9). For example, recent work has suggested that CB1-cannabinoid receptors on the tongue mediate neural activity elicited by a palatable sweet taste (10). Gustatory neural signals from nutrients, including fats and sugars, are transmitted from the oral cavity to the brain via cranial nerves V, VII, IX, and X (11). In particular, cranial nerve X, also termed the vagus nerve, contains branches that communicate efferent and afferent food-related signals between brain and gut (12). To isolate early orosensory signals from subsequent postigestive influences, we used sham feeding in rats, a well-characterized experimental model in which liquid diets are drained from the stomach through a chronically implanted gastric cannula (ref. 9; Fig. S1).

Results

Orosensory Properties of Fat Mobilize Small-Intestinal Endocannabinoids. We allowed rats to sham ingest a corn oil emulsion and measured endocannabinoid content in various brain regions and in peripheral tissues by liquid chromatography/mass spectrometry. Surprisingly, fat sham feeding selectively increased levels of 2-AG and anandamide in the jejunal segment of the gastrointestinal tract (Fig. 1 A and B, 1), but not in other peripheral tissues or brain regions included in our survey (Fig. 2). A similar response was elicited by a nutritionally complete liquid diet (Fig. 1 A and B, 2), whereas sugar (Fig. 1 A, B, 3) or protein solutions were ineffective (Fig. 1 A and B, 4). Irrespective of nutrient composition, sham feeding failed to alter jejunal content of oleoyl ethanolamide, a lipid-derived satiety factor formed in enterocytes when dietary fat enters the small intestine (ref. 13; Table S1). Notably, severing the vagus nerve below the diaphragm abolished the ability of fat to initiate small-intestinal endocannabinoid production (Fig. S2), which indicates that neural communication from the brain to the gut via the vagus nerve is necessary to drive this biochemical reaction. These findings suggest that cephalic signals elicited by sham feeding of fat, but not other nutrients, selectively mobilize endocannabinoids in the upper gut through a mechanism that is mediated by efferent vagal fibers.

Sham-Fat Intake Modifies Intestinal Endocannabinoid Metabolism. Biochemical tests showed that fat sham ingestion enhances jejunal endocannabinoid mobilization through a concerted action on the biosynthesis and degradation of these lipid-derived mediators. Fat sham intake decreased 2-AG-hydrolyzing activity in jejunum (Fig. 3A, 1), without influencing activities involved in generating 2-AG (Fig. 3A, 2) or its precursor, 1-stearoyl-2-arachidonoyl-sn-glycerol (Fig. 3A, 3). Moreover, fat sham intake lowered anandamide-hydrolyzing activity (Fig. 3B, 1), whereas elevating the activity involved in producing anandamide (Fig. 3B, 2).

Author contributions: N.V.D. and D.P. designed research; N.V.D. and X.L. performed research; G.S. and X.L. contributed new reagents/analytic tools; N.V.D., G.A., and D.P. analyzed data; and N.V.D. and D.P. wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

1To whom correspondence should be addressed. E-mail: piomelli@uci.edu.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1104675108/-/DCSupplemental.
Receptors Control Sham Fat Intake.

To examine whether small-intestinal endocannabinoid release regulates fat intake, we measured sham feeding of corn oil while infusing into the rat duodenum an isotonic solution containing the CB1-type cannabinoid receptor antagonist/inverse agonist, rimonabant. Intraduodenal rimonabant was less potent at reducing normal feeding of standard chow than at decreasing fat sham ingestion (Fig. 4A). The high potency of this effect (median effective dose, ED$_{50}$, 0.3 mg/kg) suggests that intraduodenal rimonabant antagonized endocannabinoid signals elicited in the gut by fat sham ingestion rather than acting at central sites. Two additional findings supported this possibility: First, intraduodenal rimonabant was less potent at reducing normal feeding of standard chow than at decreasing fat sham ingestion (Fig. 4B), and second, systemic administration of the peripherally restricted CB1-receptor neutral antagonist, URB447 (14), was also effective at suppressing fat sham intake (Fig. 4C). The latter effect further suggests that pharmacological treatments reduced fat intake by blocking endocannabinoid signaling at CB1 receptors, rather than inverse agonism of CB1 receptors, which may have occurred with rimonabant. URB447 displays a weak CB1-receptor agonist activity in vitro (14); however, systemic treatment with an effective dose of the CB1-receptor agonist, JWH-015 (15), failed to modify fat sham intake (Fig. S3). Thus, it is unlikely that URB447 reduced fat intake by acting as an agonist at gut CB1 receptors. We interpret this set of results to indicate that endocannabinoid signaling at CB1 receptors in the gut plays an essential role in driving fat sham feeding.

**Discussion**

In this work, we have shown that oral exposure to fat stimulates mobilization of the endocannabinoids 2-AG and anandamide in the rat small intestine and that localized functional blockade of this signaling event suppresses fat sham feeding. Our findings identify the gut endocannabinoid system as a critical component of the positive feedback mechanism that drives fat intake and suggest that therapeutic strategies aimed at restraining small-intestinal endocannabinoid activity might help to selectively reduce the overeating of fatty foods. Previous experiments in rats have shown that the orosensory properties of fat are sufficient to maintain sham intake once it has
began (9) and that oral stimulation is necessary to elicit conditioned place preference to this nutrient (16). Moreover, oral exposure to fat stimulates dopamine outflow in the ventral striatum (17), a brain region that is critical for the evaluation of rewarding sensory stimuli (18). These data support the theory (9) that cephalic-positive feedback mechanisms play a key role in the rewarding properties of fat-rich foods. Our study identifies the intestinal endocannabinoid system as an essential component of this process. Endocannabinoids and their attending cell-surface receptors are found throughout the body and are known to participate in the control of food intake (2, 19). Although much attention has focused on endocannabinoid signaling in the brain (19), the role of peripheral endocannabinoids in food intake is increasingly recognized (20–22). For example, small-intestinal levels of 2-AG and anandamide rise during food deprivation and fall upon refueling, suggesting that they may signal energy imbalance and promote caloric intake (21, 23). Furthermore, a fat-rich diet modifies intestinal endocannabinoid levels (23, 24). Our studies uncovered an unexpected role for small-intestinal endocannabinoids in controlling the intake of dietary fat driven by oral exposure to this nutrient. Our results, combined with those of prior studies (21, 23), suggest that elevations in intestinal 2-AG and anandamide levels might contribute to the orosensory-mediated induction of fat intake, whereas reductions in the intestinal levels of the same compounds might participate in meal termination. A full test of this hypothesis will require, however, additional experiments.

Based on the present findings, it is reasonable to hypothesize that 2-AG and anandamide act by engaging CB1 receptors, which are present on enteric neurons and vagal fibers (20), thus modifying the generation or action of neurohumoral factors that affect satiation (meal size) and satiety (intermeal interval), such as ghrelin (25). Although the identification of these factors must await future experimentation, our study does suggest that pharmacological strategies aimed at curbing endocannabinoid activity in the gut might selectively lower the intake of fat-rich foods, a major drive behind overweight and obesity, without affecting reward systems in the brain.

Materials

Animals. Adult male Sprague–Dawley rats (250–300 g) were purchased from Charles River and housed at room temperature (22 °C) in individual stainless-steel suspension cages consisting of wire bottoms to prevent coprophagia. Rats were maintained on a 12-h light/dark cycle (on at 0630 hours and off at 1830), and had free access to water and standard chow pellets (Research Diets) throughout the entire study, until two days before testing (see Test Diets and Feeding Schedule below for more details). All procedures met the National Institutes of Health guidelines for the care and use of laboratory animals and were approved by the Institutional Animal Care and Use Committee of the University of California, Irvine.

Chemicals. Rimonabant was kindly supplied by the National Institute on Drug Abuse and prepared in 5% propylene glycol, 5% Tween-80, and sterile saline. Rimonabant was administered through intraduodenal (distal) catheters in a volume of 2 mL/kg. URB447 (Cayman Chemical) and JWH-015 (Tocris) were dissolved in 100% DMSO (Sigma-Aldrich) and administered by i.p. injection in a volume of 1 mL/kg. All corresponding vehicle treatments for each compound listed above was administered as described, except no drug was present.

Test Diets and Feeding Schedule. Two days before testing, animals began a feeding schedule with free access to standard rodent chow for 6 h (1200–1800 hours). This schedule was maintained daily throughout the duration of testing. Separate groups of animals were sham fed for 30 min (1000–1030 hours) four separate liquid diets: Vanilla Ensure (10 mL; Abbott Nutrition), corn oil emulsion (10 mL at 25% vol/vol; Fisher Scientific), sucrose solution (15 mL at 8% wt/vol; Sigma), or peptone (10 mL at 8% wt/vol; type I enzymatic hydrolysate from meat; Sigma). The concentrations of corn oil, sucrose, and peptone were chosen based on published data indicating that these concentrations are readily sham fed by rats (26–28). The lipid emulsion was prepared (29) by adding an emulsifier (Emplex, 0.4% wt/vol; kindly donated by Caravan Ingredients) to distilled water, followed by heating in a microwave oven for 45 s. An appropriate quantity of corn oil was added to this mixture and homogenized for 5 min by using a rotor-stator homogenizer at 20,000 rpm (Polytron PT 6100). The oil emulsion was allowed to cool on ice for 10 min. All test diets were prepared daily and were at room temperature at the time of presentation to animals.

Sham-Feeding Procedure. In the sham-feeding paradigm, nutrients pass through the mouth and esophagus and, subsequently, drain out of the stomach via gastric cannulae (Fig. S1). Extensive prior work with this model has shown that postingestive influences from the diets are removed (9). This work was confirmed experimentally here by showing that fat sham feeding failed to alter jejunal levels of the satiety factor, oleoylethanolamide (Table S1), which is produced when lipids enter the small intestine (13, 30). On test days, animals were placed in individual plastic suspension cages (with a 2-cm wide slit running the entire length of the floor of the cage) one hour (0900) before testing and returned to their metal suspension cages just after completion of testing (1100). The sham-feeding protocol used in this investigation was based on the procedure outlined by G.P. Smith (31). After the 1-h daily acclimation period to the test cages, the stainless-steel plugs were removed from the gastric cannulae, and the stomachs were flushed with saline until the water flowed free of any particles (≤20 mL). A stainless-steel tube (1.5 cm in length) was fitted to silastic tubing (25 cm in length, 0.040 inch i. d., 0.085 inch o.d.), threaded into the gastric cannulae, and the tubing placed through the slit in the bottom of the cage allowing the animal to move freely while feeding. Animals were given access to the liquid test diets in small sipper tubes and were allowed to sham feed for 30 min. The liquid diets drained into a plastic container placed just beneath each cage. After the test sessions, the drainage tubes were removed, stomachs were flushed, and the stainless-steel plugs were threaded back into the gastric cannulae. Animals were returned to their home cages and given free access to standard chow for 6 h.

Methods

Gastric Cannulae. The surgical implantation of stainless-steel gastric cannulae into the stomach was performed as described (31). Animals were anesthetized with an i.p. injection of ketamine (100 mg/kg) and xylazine (10 mg/
kg; Western Medical Supply). An incision was made through the skin and abdominal muscle 0.5 cm to the left of midline, and the stomach and spleen were removed. The method greatly reduces morphological changes that can occur in brains snap-frozen in liquid N₂. All tissues were subsequently stored at −80 °C until time of processing.

Effects of CB1 cannabinoid receptor blockade in the proximal-small intestine on sham feeding of fat and real feeding of standard chow. Animals were maintained on the same daily feeding schedule throughout testing as described above for sham feeding (Test Diets and Feeding Schedule), except that each animal was presented with 40 mL of corn oil emulsion. After 4 d of sham feeding (three separate groups of animals), at which time all animals readily consumed at least 10 mL, animals received (day five) a vehicle infusion (intraduodenal) or injection (intraperitoneal) (Chemicals for Corresponding Vehicle) 15 min before the sham feeding procedure, and oil intake was recorded for the 30-min test. Twenty-four hours later, each group received rimonabant (intraduodenal infusion), URB497 (IP injection), or JWH-015 (IP injection) (same three separate groups that received their corresponding vehicle, as described above), and fat intake was recorded during the 30-min sham-feeding test. A fourth group of animals was tested for the effects of intraduodenal rimonabant treatment on 30-min normal intake of standard chow. This group was maintained on the same feeding and vehicle/drug-treatment schedule as all other groups listed above. Rimonabant was administered 15 min before their daily presentation of standard chow (1200 hours), and subsequent 30-min intakes of Chow were recorded. All animals within all groups received all doses of corresponding drug and vehicle, with at least 72 h separating drug treatments. Within an experimental group, vehicle-treatment intakes for each corresponding drug dose were averaged together for statistical comparison versus drug doses.

Lipid Extractions. Frozen tissues were weighed and homogenized in 0.6 mL of methanol containing the following internal standards: [1H₂]-oleoylthanolamide (retention time 13.5 min; Zorbax), eluted by a gradient of methanol in water (from 85 to 90% methanol in 2.5 min) at a flow rate of 1.5 mL/min. Column temperature was kept at 40 °C. MS detection was in the positive ionization mode, capillary voltage was set at 3 kV, and fragmentor voltage at 120 V. Lipids were quantified with an isotope-dilution method (34) monitoring sodium adducts of the molecular ions [M+N⁺] in the selected ion-monitoring (SIM) mode.

N-Acyl Phosphatidylethanolamine (NAPE). We used a 1100 liquid chromatography system coupled to a XIC Ion Trap MS detector (Agilent Technologies) equipped with an electrospray ionization (ESI) interface. Lipids were separated on a XDB Eclipse C₁₈ column (50 × 4.6 mm i.d., 1.8 μm, Zorbax), eluted by a gradient of methanol in water (from 85 to 90% methanol in 2.5 min) at a flow rate of 1.5 mL/min. NAPe detection was identified by retention time and [M+H]⁺ properties, as described (32). Extracted ion chromatograms were used to quantify each precursor ion by the following characteristic product ions: 1-stearoyl-2-arachidonoyl-sn-glycero-phosphethanolamine-N-arachidonoyl (m/z = 1,076.8 > 766.8), and 1,2-dipalmitoyl-sn-glycero-3-phosph ethanolamine-N-heptadecanoyl (m/z = 914.8 > 676.6), which was used as an internal standard (35).

1,2-Diacylglycerol (DAG). We used an Agilent 1100 LC-MS system coupled to a MS detector Ion-Trap XCT interfaced with ESI (Agilent Technologies). DAG species were separated by using a XDB Eclipse C₁₈ column (50 × 4.6 mm i.d., 1.8 μm; Zorbax), eluted by a gradient of methanol in water (from 85 to 90% methanol in 2.5 min) at a flow rate of 1.5 mL/min. Column temperature was kept at 40 °C. The capillary voltage was set at 4.0 kV and skimmer voltage at 40 V. N₂ was used as drying gas at a flow rate of 12 L/min, temperature at 350 °C, and nebulizer pressure at 80 psi. Helium was used as collision gas, and fragmentation amplitude was set at 1.2 V. DAG were identified in the positive ionization mode based on their retention times and MS² properties, using synthetic standards as references. Multiple reaction monitoring was

Experimental Design. Influence of the cephalic phase of feeding on endocannabinoid content in brain and peripheral tissues. Separate groups of animals were sham-fed (30 min, 1000–1030 hours) for four consecutive days (all animals consumed the full amount of liquid diet presented by day four), four separate liquid diets in a small sipper tube: Vanilla Ensure (10 mL); a corn oil emulsion (10 mL); a sucrose solution (15 mL), or a peptone solution (10 mL). On the fifth day of sham feeding, half of each group received the test diet for 30 min, and the other half received an empty sipper tube for 30 min. Immediately after this final 30-min sham-feeding session, animals were anesthetized with isoflurane, and peripheral tissues including tongue, stomach, pancreas, liver,
used to acquire full-scan tandem MS spectra of selected DAG ions. Extracted ion chromatograms were used to quantify 1-stearoyl-2-arachidonoyl-sn-glycerol (m/z = 667.8 ± 341.5) and dinonadecadienoic (m/z = 667.8 ± 367.3), which was used as an internal standard.

N-Arachidonoyl Phosphatidylethanolamine-Specific Phospholipase D Activity. Jejunal tissue was homogenized in ice-cold Tris-HCl (50 mM at pH 7.5, 10 vol) containing 0.32 M sucrose. Homogenates were centrifuged at 1,000 × g for 10 min and supernatants (0.1 mg of protein) were incubated at 37 °C for 30 min in Tris-HCl (50 mM at pH 7.4, 0.2 mL) containing 0.1% Triton X-100, phenylmethylsulphonylfluoride (1 mM) and 1,2-dipalmitoyl-sn-glycer-3-phosphoethanolamine-N-phenylcyclohexylamine-3 (1 mM) for 30 min at 25 °C in 0.5 M of 50 mM Tris HCl buffer (pH 8.0) containing fatty acid-free BSA (0.05% weight/vol). Reactions were terminated adding 1.5 mL of chloroform/methanol (2:1, vol/vol), and phases were separated by centrifugation. The aqueous layers were collected, and [3H]-ethanolamine was quantified by liquid scintillation counting.

DAG Lipase Activity. Jejunal tissue was homogenized in ice-cold Tris-HCl (50 mM, pH 7.5, 10 vol) containing 0.32 M sucrose. Homogenates were centrifuged at 1,000 × g for 10 min, and the supernatants (0.1 mg of protein) were incubated with [3H]-ethanolamine was quantified by liquid scintillation counting.

Statistical Analyses. Results are expressed as the mean ± SEM. The significance of differences between groups was evaluated by Student’s t test, or a one- or two-way analysis of variance followed by Tukey’s post hoc test or Bonferroni’s post hoc test for multiple comparisons. In the comparison of means when significant differences were found, analyses were made by using GraphPad Prism software (GraphPad Software), and differences were considered significant if P < 0.05.

ACKNOWLEDGMENTS. We thank Dr. Jonathan A. Phillips for helpful discussions. This work was supported by the National Institutes of Health Grants DK073955, AA012413, and 1R1AA017538 (to D.P.).